Inventiva (IVA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inventiva S.A., a French biopharmaceutical company, has initiated a limited offering of 201 royalty certificates at a subscription price of €100,000 each, aiming to raise €20.1 million from certain investors. The royalty certificates, which are subject to specific terms and conditions, will be electronically signed and legally recognized. The closing of this transaction is contingent on the fulfillment of certain conditions, including the receipt of the aggregate subscription price and regulatory approval.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.